Stephens Investment Management Group LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 290,354 shares of the medical device company’s stock after purchasing an additional 15,007 shares during the period. Stephens Investment Management Group LLC owned about 0.32% of DexCom worth $43,507,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of DXCM. Gradient Investments LLC bought a new position in shares of DexCom during the second quarter worth about $25,000. Steward Partners Investment Advisory LLC bought a new position in shares of DexCom during the second quarter worth about $31,000. Private Ocean LLC bought a new position in shares of DexCom during the first quarter worth about $36,000. Wealthcare Advisory Partners LLC bought a new position in shares of DexCom during the second quarter worth about $37,000. Finally, Bremer Bank National Association bought a new position in shares of DexCom during the first quarter worth about $42,000. 96.13% of the stock is currently owned by institutional investors and hedge funds.
In other DexCom news, EVP Steven Robert Pacelli sold 3,597 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $116.71, for a total value of $419,805.87. Following the sale, the executive vice president now owns 72,570 shares in the company, valued at $8,469,644.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew K. Balo sold 7,825 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $125.00, for a total transaction of $978,125.00. The disclosure for this sale can be found here. Insiders sold 55,665 shares of company stock worth $7,344,275 in the last 90 days. 1.80% of the stock is owned by company insiders.
Several equities analysts have recently commented on the stock. UBS Group increased their price target on shares of DexCom from $140.00 to $160.00 and gave the stock a “neutral” rating in a research report on Thursday, August 1st. Zacks Investment Research cut shares of DexCom from a “buy” rating to a “hold” rating and set a $163.00 price target on the stock. in a research report on Monday. Raymond James raised their target price on shares of DexCom from $150.00 to $172.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Bank of America raised their target price on shares of DexCom from $162.00 to $185.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, Oppenheimer raised their target price on shares of DexCom from $167.00 to $180.00 in a report on Thursday, August 1st. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $166.75.
Shares of NASDAQ:DXCM traded up $3.37 during trading hours on Thursday, hitting $156.87. The stock had a trading volume of 11,286 shares, compared to its average volume of 903,495. The firm has a fifty day moving average price of $150.23. DexCom, Inc. has a 1-year low of $105.05 and a 1-year high of $161.30. The firm has a market capitalization of $14.00 billion, a price-to-earnings ratio of 521.66 and a beta of 0.80. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.01 by $0.07. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The company had revenue of $336.40 million for the quarter, compared to analyst estimates of $304.40 million. During the same quarter last year, the business earned ($0.10) earnings per share. DexCom’s revenue was up 38.7% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom, Inc. will post 0.97 EPS for the current fiscal year.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: What is a Derivative?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.